Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cellular accumulation of the anticancer agent cisplatin: a review.

Literature DB >> 8512802

Cellular accumulation of the anticancer agent cisplatin: a review.

Abstract

Acquired resistance to cisplatin (DDP) is a major clinical problem in the treatment of ovarian, testicular, and head and neck carcinomas; decreased accumulation of DDP is the most consistently observed alteration in resistant cells. It has been postulated that DDP enters the cell by passive diffusion based on the observations that DDP accumulation is proportional to the drug concentration, accumulation is not saturable, and that structural analogs of DDP do not inhibit accumulation. However, recent studies show that DDP accumulation can be specifically stimulated or inhibited by pharmacological agents and the activation of signal transduction pathways. This paper reviews the existing data on the mechanism of DDP accumulation and develops the postulate that some component of transport occurs through a gated ion channel.

Entities: Chemical Disease

Mesh：

Substances：
Cisplatin

Year: 1993 PMID： 8512802 PMCID： PMC1968522 DOI： 10.1038/bjc.1993.221

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

35 in total

1. Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents.

Authors: G R Gale; C R Morris; L M Atkins; A B Smith
Journal: Cancer Res Date: 1973-04 Impact factor: 12.701

2. Carrier-dependent and carrier-independent transport of anti-cancer alkylating agents.

Authors: J E Byfield; P M Calabro-Jones
Journal: Nature Date: 1981-11-19 Impact factor: 49.962

3. Decreased cisplatin uptake by resistant L1210 leukemia cells.

Authors: R A Hromas; J A North; C P Burns
Journal: Cancer Lett Date: 1987-08 Impact factor: 8.679

4. The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.

Authors: M C Nicolson; R M Orr; C F O'Neill; K R Harrap
Journal: Neoplasma Date: 1992 Impact factor: 2.575

5. Increase in cis-dichlorodiammineplatinum (II) cytotoxicity upon reversible electropermeabilization of the plasma membrane in cultured human NHIK 3025 cells.

Authors: J E Melvik; E O Pettersen; P B Gordon; P O Seglen
Journal: Eur J Cancer Clin Oncol Date: 1986-12

6. Reduction of cis-dichlorodiammineplatinum-induced cell inactivation by benzaldehyde.

Authors: J M Dornish; E O Pettersen; R Oftebro; J E Melvik
Journal: Eur J Cancer Clin Oncol Date: 1984-10

7. Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II).

Authors: S Shionoya; Y Lu; K J Scanlon
Journal: Cancer Res Date: 1986-07 Impact factor: 12.701

8. Reduced cellular uptake of cis-dichlorodiammine-platinum by benzaldehyde.

Authors: J M Dornish; J E Melvik; E O Pettersen
Journal: Anticancer Res Date: 1986 Jul-Aug Impact factor: 2.480

9. Protection from cis-dichlorodiammineplatinum-induced cell inactivation by aldehydes involves cell membrane amino groups.

Authors: J M Dornish; E O Pettersen
Journal: Cancer Lett Date: 1985-12 Impact factor: 8.679

10. Synergistic cell inactivation by cis-dichlorodiammineplatinum in combination with 1-propargyl-5-chloropyrimidin-2-one.

Authors: J M Dornish; E O Pettersen; R Oftebro
Journal: Br J Cancer Date: 1987-09 Impact factor: 7.640

110 in total

Cellular accumulation of the anticancer agent cisplatin: a review.

1. Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents.

2. Carrier-dependent and carrier-independent transport of anti-cancer alkylating agents.

3. Decreased cisplatin uptake by resistant L1210 leukemia cells.

4. The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.

5. Increase in cis-dichlorodiammineplatinum (II) cytotoxicity upon reversible electropermeabilization of the plasma membrane in cultured human NHIK 3025 cells.

6. Reduction of cis-dichlorodiammineplatinum-induced cell inactivation by benzaldehyde.

7. Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II).

8. Reduced cellular uptake of cis-dichlorodiammine-platinum by benzaldehyde.

9. Protection from cis-dichlorodiammineplatinum-induced cell inactivation by aldehydes involves cell membrane amino groups.

10. Synergistic cell inactivation by cis-dichlorodiammineplatinum in combination with 1-propargyl-5-chloropyrimidin-2-one.

1. Apoptosis-related mRNA expression profiles of ovarian cancer cell lines following cisplatin treatment.

Review 2. New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA.

3. Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells.

4. Chemotherapy agents: a primer for the interventional radiologist.

5. Synthesis, characterization, and biological activity of platinum II, III, and IV pivaloamidine complexes.

6. Ultrasound image-guided therapy enhances antitumor effect of cisplatin.

7. In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.

8. Detection of platinum-DNA adducts by 32P-postlabelling.

Review 9. The path for metal complexes to a DNA target.

10. Cellular responses to Cisplatin-induced DNA damage.